Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

Nature

Volumn 501, Issue 7467, 2013, Pages 439-443

  Corti, Davide ^a,b   Bianchi, Siro ^a   Vanzetta, Fabrizia ^a   Minola, Andrea ^b   Perez, Laurent ^b   Agatic, Gloria ^a   Guarino, Barbara ^a   Silacci, Chiara ^b   Marcandalli, Jessica ^b   Marsland, Benjamin J ^c   Piralla, Antonio ^d   Percivalle, Elena ^d   Sallusto, Federica ^b   Baldanti, Fausto ^d   Lanzavecchia, Antonio ^b,e  

^a Humabs BioMed SA ^*  (Switzerland)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY MPE8; UNCLASSIFIED DRUG;

ANTIBODY; DISEASE; INFLUENZA; PNEUMONIA; PROTEIN; VACCINE; VIRUS;

ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN METAPNEUMOVIRUS; IMMUNE EVASION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS CROSS NEUTRALIZATION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CATTLE; CROSS REACTIONS; EPITOPES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; METAPNEUMOVIRUS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MURINE PNEUMONIA VIRUS; PARAMYXOVIRIDAE; PARAMYXOVIRIDAE INFECTIONS; PNEUMOVIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, BOVINE; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS; VIRAL VACCINES;

ANIMALIA; BOVINE RESPIRATORY SYNCYTIAL VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN METAPNEUMOVIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDRANGEA RINGSPOT VIRUS; MURINE PNEUMONIA VIRUS; POTATO VIRUS M; RICE STRIPE VIRUS;

EID: 84884413000     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12442     Document Type: Article

References (35)

1. Corti, D. & Lanzavecchia, A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705-742 (2013)
2. Hall, C. B. et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360, 588-598 (2009)
3. Edwards, K. M. et al. Burden of human metapneumovirus infection in young children. N. Engl. J. Med. 368, 633-643 (2013)
4. Williams, J. V. et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N. Engl. J. Med. 350, 443-450 (2004)
5. Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749-1759 (2005)
6. Edwards, M. R., Bartlett, N. W., Hussell, T., Openshaw, P. & Johnston, S. L. The microbiology of asthma. Nature Rev. Immunol. 10, 459-471 (2012)
7. Wyde, P. R., Chetty, S. N., Jewell, A. M., Boivin, G. & Piedra, P. A. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 60, 51-59 (2003)
8. Collins, P. L.&Crowe, J. E. Jr. in Fields Virology 6th edn. (edsKnipe D. M.&Howley P. M.) Respiratory syncytial virus and metapneumovirus (Lippincott Williams & Wilkins, 2013)
9. van den Hoogen, B. G. et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nature Med. 7, 719-724 (2001)
10. Groothuis, J. R., Simoes, E. A., Hemming, V. G. & Respiratory Syncytial Virus Immune Globulin Study Group. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 95, 463-467 (1995)
11. The-IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537 (1998)
12. de Fontbrune, F. S. et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stemcell transplantation. Clin. Infect. Dis. 45, 1019-1024 (2007)
13. Adams, O. et al. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin. Infect. Dis. 51, 185-188 (2010)
14. Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Med. 10, 871-875 (2004)
15. Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nature Med. 16, 123-128 (2010)
16. Ulbrandt, N. D. et al. Isolation andcharacterization ofmonoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J. Virol. 80, 7799-7806 (2006)
17. Beeler, J. A.&vanWykeCoelingh, K.Neutralizationepitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63, 2941-2950 (1989)
18. Magro, M. et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl Acad. Sci. USA 109, 3089-3094 (2012)
19. Swanson, K. A. et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl Acad. Sci. USA 108, 9619-9624 (2011)
20. Calder, L. J. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271, 122-131 (2000)
21. Connolly, S. A., Leser, G. P., Yin, H.-S., Jardetzky, T. S. & Lamb, R. A. Refolding of a paramyxovirus F protein fromprefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc. Natl Acad. Sci. USA 103, 17903-17908 (2006)
22. McLellan, J. S. et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J. Virol. 84, 12236-12244 (2010)
23. McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013)
24. Zhu, Q. et al. Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J. Infect. Dis. 205, 635-638 (2012)
25. Zhao, X. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318, 608-612 (2004)
26. Durbin, J. E. et al. The role of IFN in respiratory syncytial virus pathogenesis. J. Immunol. 168, 2944-2952 (2002)
27. Domachowske, J. B., Bonville, C. A. & Rosenberg, H. F. Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr. Infect. Dis. J. 23, S228-S234 (2004)
28. Shah, J. N. & Chemaly, R. F. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 117, 2755-2763 (2011)
29. Bonville, C. A. et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J. Virol. 78, 7984-7989 (2004)
30. Greensill, J. et al. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg. Infect. Dis. 9, 372-375 (2003)
31. Tiller, T. et al. Efficient generation ofmonoclonal antibodies fromsingle humanB cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112-124 (2008)
32. Lefranc, M.-P. et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 37, D1006-D1012 (2009)
33. Tamura, K. et al. MEGA5: molecular evolutionary genetics analysis using maximumlikelihood, evolutionary distance, andmaximumparsimonymethods. Mol. Biol. Evol. 28, 2731-2739 (2011)
34. Timmerman, P., Puijk, W. C. & Meloen, R. H. Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology. J. Mol. Recognit. 20, 283-299 (2007)
35. Slootstra, J. W., Puijk, W. C., Ligtvoet, G. J., Langeveld, J. P. & Meloen, R. H. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol. Divers. 1, 87-96 (1996).